James Manuso

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Part of Servoca Plc, Eurogen Ltd designs software. The company is based in Pulborough, UK. Eurogen was acquired by Multi Group Plc on December 11, 2000 for $0.40 million.

Galenica Pharmaceuticals, Inc. develops vaccines. The company was founded by Jacques Marcotte and James S. Manuso and is headquartered in Birmingham, AL.

Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada.

Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.

ZyStor Therapeutics, Inc. develops innovative therapeutics. It offers enzyme replacement therapies for the treatment of lysosomal storage diseases. The company was founded by Brian L. Clevinger, James S. Manuso and Allan R. Goldberg and is headquartered in Milwaukee, WI.

Montigen Pharmaceuticals, Inc. developed pharmaceutical products used for the treatment of cancer. Its products addressed oncology drug market with demonstrated preclinical activity in various solid tumor types, including pancreatic, colorectal, breast, prostate, and ovarian cancers. The company was founded in 2003 and was headquartered in Salt Lake City, UT.

The Channel Group is a venture management and corporate advisory business headquartered in Harrison, New York.

Part of AAON, Inc., AAON Coil Products, Inc. manufactures and markets air-conditioning and heating equipment. The company is based in Longview, TX. Gary D. Fields has been the CEO of the company since 2018.

Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA.

OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI.